Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

(2023) Patricia Winokur et al.   NEW ENGLAND JOURNAL OF MEDICINE

Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2

(2022) Marie E. Bonhomme et al.   PLoS One

In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis

(2022) Shelly Bolotin et al.   JOURNAL OF INFECTIOUS DISEASES

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

(2022) Dean Follmann et al.   ANNALS OF INTERNAL MEDICINE

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

(2022) Yunlong Cao et al.   NATURE

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

(2022) Suzanne M. Scheaffer et al.   NATURE MEDICINE

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

(2022) Spyros Chalkias et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

(2022) Mark W. Tenforde et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

(2022) Ruth Link-Gelles et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022

(2022) Diya Surie et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

(2021) Hana M. El Sahly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE